Your browser is no longer supported. Please, upgrade your browser.
Settings
PMVP [NASD]
PMV Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)- Insider Own5.70% Shs Outstand44.77M Perf Week7.96%
Market Cap1.70B Forward P/E- EPS next Y-2.30 Insider Trans0.00% Shs Float20.26M Perf Month-7.39%
Income- PEG- EPS next Q-0.57 Inst Own83.50% Short Float7.79% Perf Quarter20.62%
Sales- P/S- EPS this Y-44.60% Inst Trans5.84% Short Ratio9.40 Perf Half Y-
Book/sh61.27 P/B0.64 EPS next Y-11.20% ROA- Target Price61.33 Perf Year-
Cash/sh8.61 P/C4.55 EPS next 5Y23.80% ROE- 52W Range31.05 - 63.22 Perf YTD-36.27%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-37.99% Beta-
Dividend %- Quick Ratio68.20 Sales past 5Y- Gross Margin- 52W Low26.25% ATR3.42
Employees39 Current Ratio68.20 Sales Q/Q- Oper. Margin- RSI (14)48.31 Volatility10.00% 8.90%
OptionableNo Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume0.34 Prev Close36.77
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume167.84K Price39.20
Recom2.00 SMA203.26% SMA50-11.03% SMA200-1.69% Volume56,466 Change6.61%
Oct-20-20Initiated Goldman Neutral $34
Oct-20-20Initiated Evercore ISI Outperform $60
Oct-20-20Initiated Cowen Outperform
Oct-20-20Initiated BofA Securities Buy $42
Feb-16-21 08:00AM  
Dec-25-20 03:44AM  
Dec-16-20 03:19PM  
Nov-24-20 05:00PM  
Nov-23-20 08:00AM  
Nov-13-20 08:00AM  
Oct-13-20 08:00AM  
Oct-09-20 03:41PM  
Oct-01-20 11:57AM  
Sep-29-20 04:05PM  
Sep-25-20 02:31PM  
12:37PM  
06:16AM  
Sep-24-20 08:06PM  
PMV Pharmaceuticals, Inc., a precision oncology company, discovery and development of small molecule, tumor-agnostic therapies for p53 mutations in cancer. Its lead product candidate is PC14586, a small molecule that corrects and restores p53 function. The company also develops product candidates for p53 R273H hotspot mutation and other p53 hotspot mutations. PMV Pharmaceuticals, Inc. was formerly known as PJ Pharmaceuticals, Inc. and changed to in July 2013. The company was founded in 2013 and is headquartered in Cranbury, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kung WinstonCOO, CFODec 08Option Exercise3.221,6005,1521,600Dec 31 04:25 PM
Mack David HenryPresident and CEONov 18Option Exercise0.532,4701,3092,470Nov 20 04:12 PM